Scottish biotechnology company NanoGenics has announced that its gene therapy technology LipTide-ECP105 significantly improves the outcomes of glaucoma surgery.
The breakthrough technology is expected to provide a more targeted and less toxic option for improvement in the outcomes.
LipTide, which is an artificial virus, acts as a custom-built delivery system that can be modified to target cells of various types and deliver different payloads.
It is a peptide-based nanoparticle and mimics natural viruses, but by-passes several viral delivery problems.
NanoGenics noted that the ability to dose gene therapy payloads on a regular basis with LipTide may revolutionise the approach to gene therapy.
Nanogenics CEO Dr Alan Walker said: “I am delighted that we have been able to demonstrate the benefits of this approach.
“It will offer real hope to those millions of patients undergoing surgery for their glaucoma, giving them and their doctors more confidence that the surgery will be more successful.
“This is a tremendous validation of our technology and we are now seeking a partner to take our other major products into further development.”
Glaucoma, which is caused by an increase in the internal pressure in the eye, is the major cause of irreversible blindness and affects more than 60 million people across the globe.
Known as trabeculectomy, the surgical procedure involves putting a tiny hole known as a ‘bleb’ in the base of the eye and is kept open for a successful surgery.
NanoGenics chief scientific officer Dr Simon Newman said: “We are pleased to see these results in this important therapeutic area.”